GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Monogram Orthopaedics Inc (NAS:MGRM) » Definitions » Cash Ratio

Monogram Orthopaedics (Monogram Orthopaedics) Cash Ratio : 4.82 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Monogram Orthopaedics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Monogram Orthopaedics's Cash Ratio for the quarter that ended in Dec. 2023 was 4.82.

Monogram Orthopaedics has a Cash Ratio of 4.82. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Monogram Orthopaedics's Cash Ratio or its related term are showing as below:

MGRM' s Cash Ratio Range Over the Past 10 Years
Min: 0.39   Med: 1.16   Max: 4.92
Current: 4.82

During the past 7 years, Monogram Orthopaedics's highest Cash Ratio was 4.92. The lowest was 0.39. And the median was 1.16.

MGRM's Cash Ratio is ranked better than
82.22% of 855 companies
in the Medical Devices & Instruments industry
Industry Median: 1.23 vs MGRM: 4.82

Monogram Orthopaedics Cash Ratio Historical Data

The historical data trend for Monogram Orthopaedics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Monogram Orthopaedics Cash Ratio Chart

Monogram Orthopaedics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial 0.81 1.88 1.09 1.16 4.82

Monogram Orthopaedics Quarterly Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.16 0.83 2.12 2.49 4.82

Competitive Comparison of Monogram Orthopaedics's Cash Ratio

For the Medical Devices subindustry, Monogram Orthopaedics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Monogram Orthopaedics's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Monogram Orthopaedics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Monogram Orthopaedics's Cash Ratio falls into.



Monogram Orthopaedics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Monogram Orthopaedics's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=13.589/2.818
=4.82

Monogram Orthopaedics's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=13.589/2.818
=4.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Monogram Orthopaedics  (NAS:MGRM) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Monogram Orthopaedics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Monogram Orthopaedics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Monogram Orthopaedics (Monogram Orthopaedics) Business Description

Traded in Other Exchanges
Address
3913 Todd Lane, Suite 307, Austin, TX, USA, 78744
Monogram Orthopaedics Inc develops a product solution architecture to enable patient-optimized orthopedic implants at scale by linking 3D printing and robotics with advanced pre-operative imaging. The company has a robot prototype that can autonomously execute optimized paths for high-precision insertion of implants in synthetic bone specimens. Monogram also intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures.
Executives
Paul H Riss director
Noel Knape officer: Chief Financial Officer 3913 TODD LANE, AUSTIN TX 78744
Benjamin Sexson director, 10 percent owner, officer: Chief Executive Officer 3913 TODD LANE, AUSTIN TX 78744
Noel Goddard director 3913 TODD LANE, AUSTIN TX 78744
Kamran Shamaei officer: Chief Technology Officer 3913 TODD LANE, AUSTIN TX 78744
Douglas Unis director 3913 TODD LANE, AUSTIN TX 78744